BUSINESS EMA starts rolling review of Sinovac's COVID-19 vaccine


EMA starts rolling review of Sinovac's COVID-19 vaccine


18:56, May 04, 2021

A medical worker displays China's Sinovac COVID-19 vaccine before the vaccination at a hospital in Baku, Azerbaijan, Jan. 18, 2021. (File photo: Xinhua)

The European Medicines Agency (EMA) announced on Tuesday it had started a rolling review of an inactivated COVID-19 vaccine developed by China's Sinovac Biotech.

A rolling review is a regulatory tool that the EMA employs to accelerate the assessment of a medicinal drug amid a public health emergency.

The decision was made based on preliminary results from studies that showed that Sinovac's vaccine triggers the production of antibodies targeting the coronavirus that causes the COVID-19 disease, the EMA said in a statement.

The EMA will evaluate data as they become available; the rolling review will continue until there is enough evidence for a formal marketing authorization application for the Chinese vaccine, the agency said.

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue